Published in:
Open Access
01-12-2010 | Poster presentation
Liver safety of two nucleoside analogs plus efavirenz, nevirapine or a ritonavir-boosted protease inhibitor in HIV/HCV-coinfected drug-naïve patients
Authors:
J Macías, J Mallolas, LF López-Cortés, JA Cartón, P Domingo, S Moreno, JA Iribarren, K Neukam, A Rodrigo, MJ Jiménez-Expósito, JA Pineda
Published in:
Journal of the International AIDS Society
|
Special Issue 4/2010
Login to get access
Excerpt
A wide range of hepatotoxicity rates associated with antiretroviral drugs (ARV) has been reported in different studies. Reasons for this include diverse populations, with different prevalence of viral hepatitis coinfection, exposure to diverse ARV and variable criteria to define liver toxicity across studies. The liver safety of regimens including efavirenz (EFV), nevirapine (NVP) or boosted-protease inhibitors (PI/r) has not been compared in a single large cohort of HIV/HCV-coinfected patients with a uniform definition of hepatotoxicity. Because of this, we evaluated the incidence and risk factors for grade 3 or 4 ALT or AST elevations (TE) and grade 4 total bilirubin elevations (TBE) among ARV-naïve HIV/HCV-coinfected patients with an initial regimen including two nucleoside analogs (NRTIs) plus EFV, NVP or a PI/r. …
